STRO

Sutro Biopharma, Inc. (STRO) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for the period ended June 30, 2026. Sutro Biopharma is a clinical-stage oncology company developing site-specific antibody-drug conjugates (ADCs) using its proprietary XpressCF and XpressCF+ platforms. The company has no approved products and relies on collaboration revenue and equity financing. The reporting period reflects the aftermath of significant restructuring plans announced in March and September 2025, which deprioritized the late-stage candidate luveltamab tazevibulin (STRO-002) to focus resources on STRO-004, STRO-006, and STRO-227.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 85% in Q2 2026 compared to Q2 2025. This was primarily driven by the termination of the collaboration with Ipsen in mid-2025, which resulted in the derecognition of $53.2 million in deferred revenue in the prior year. Revenue from Astellas increased slightly due to milestone achievements.
• Restructuring Costs: Restructuring and related costs dropped significantly to $0.2 million in Q2 2026 from $18.4 million in Q2 2025. The major severance and program termination costs associated with the March and September 2025 restructuring plans were largely recognized in the prior year.
• Operating Expenses: Total operating expenses decreased 41% year-over-year in Q2, reflecting the reduced workforce and the exit of the internal manufacturing facility in late 2025.
• Capital Raise: In February 2026, the company completed an underwritten public offering, issuing approximately 7.9 million shares at $13.98 per share, generating net proceeds of approximately $102.7 million.

Outlook, Management Commentary, and Risks

• Product Pipeline:
  • STRO-004: Phase 1 trial initiated in November 2025. August 2026 data showed encouraging early clinical activity with confirmed and unconfirmed partial responses across pancreatic, head and neck, and non-small cell lung cancer. Dose optimization is ongoing.
  • STRO-006: Expected to initiate Phase 1 trial in Q3 2026.
  • STRO-227: Dual-payload ADC; IND submission anticipated in late 2026.
• Liquidity: Management believes current cash, cash equivalents, and marketable securities ($164.3 million) are sufficient to fund operations for at least 12 months following the filing date. However, the company expects to incur substantial losses and will require additional capital to advance development.
• Key Risks:
  • Profitability: History of significant losses; may never achieve profitability.
  • Development Risk: Product candidates are in early stages and may fail clinical trials or face regulatory delays.
  • Collaboration Dependence: Revenue is heavily dependent on partners (e.g., Astellas). Future milestones are uncertain.
  • Manufacturing: Reliance on third-party CMOs following the exit of internal manufacturing.
  • Deferred Royalty Obligation: Significant non-cash interest expense ($19.3 million YTD) related to the sale of future Vaxcyte royalties to Blackstone.

Investor Verification Checklist

• Verify the sustainability of the $164.3 million cash runway given the high burn rate and lack of commercial revenue.
• Monitor the Phase 1 data readout for STRO-004, specifically regarding dose-limiting toxicities and response rates in heavily pretreated patients.
• Assess the impact of the $239.1 million deferred royalty obligation on future non-cash interest expenses and net loss calculations.
• Review the status of the Astellas collaboration for upcoming milestone triggers and potential revenue recognition.
• Confirm the timeline for the STRO-006 Phase 1 initiation and STRO-227 IND submission.